Thryv Therapeutics, Inc.
Clinical trials sponsored by Thryv Therapeutics, Inc., explained in plain language.
-
New drug aims to tame dangerous heart rhythms in genetic disorder
Disease control Recruiting nowThis study tests an experimental drug, THRV-1268, in 64 people with Long QT Syndrome Type 2 (LQTS 2), a genetic heart condition that can cause dangerous rhythms and sudden cardiac arrest. Participants take the drug twice daily for up to 6 weeks to see if it safely shortens the QT…
Phase: PHASE2, PHASE3 • Sponsor: Thryv Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 08:02 UTC
-
Heart Condition's hidden toll: new study probes daily struggles of LQTS patients
Knowledge-focused Recruiting nowThis study aims to understand how Long QT Syndrome types 2 and 3 impact quality of life and daily burden. About 200 adults with a confirmed genetic diagnosis will fill out questionnaires about their well-being, emotions, and social support. No treatment is given; the goal is to g…
Sponsor: Thryv Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 08, 2026 12:02 UTC